COMMUNIQUÉS West-GlobeNewswire
-
Nordic Naturals Releases Expert Insights on Why Omega-3s Should Be on Back-to-School Checklists
24/07/2026 -
HorseFil Official Launch 2026 Effective Men's Energy and Vitality Gummies Highlights Ingredient, Supplement Facts Available in USA
24/07/2026 -
Affidea accélère sa croissance au Royaume-Uni en signant un partenariat stratégique avec LIPS Healthcare
24/07/2026 -
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
24/07/2026 -
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
24/07/2026 -
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/07/2026 -
LifeMD to Report Second Quarter 2026 Financial Results on August 5
24/07/2026 -
Sienna Announces Confirmation of Morningstar DBRS Credit Rating
24/07/2026 -
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
24/07/2026 -
Maxim Hair Restoration Named Top US Hair Restoration Brand 2026, Reinforcing Its Position Among the Best Hair Restoration Clinics in America
24/07/2026 -
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
24/07/2026 -
ColestZen Publishes Ingredient Facts for Its 18-Ingredient Supplement Formula: Serving Directions and Safety Information for 2026
24/07/2026 -
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency
24/07/2026 -
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
24/07/2026 -
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
24/07/2026 -
HorseFil Publishes Full Milligram Amounts for All Seven Ingredients: Tongkat Ali 200 mg, Serving Directions, and Safety Information for 2026
25/07/2026 -
Dyadic Announces Continued Listing on the Nasdaq Capital Market
24/07/2026 -
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
24/07/2026 -
BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe
24/07/2026
Pages